scholarly article | Q13442814 |
P356 | DOI | 10.4088/JCP.12M08084 |
P8608 | Fatcat ID | release_lzu6swqpajc3tanznjpqzi44uu |
P698 | PubMed publication ID | 23541189 |
P50 | author | Stephen Stahl | Q24006564 |
P2093 | author name string | Andrei Pikalov | |
Antony Loebel | |||
Josephine Cucchiaro | |||
Jay Hsu | |||
Doreen Simonelli | |||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | schizophrenia | Q41112 |
placebo | Q269829 | ||
P304 | page(s) | 507-515 | |
P577 | publication date | 2013-03-13 | |
P1433 | published in | The Journal of Clinical Psychiatry | Q7743563 |
P1476 | title | Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. | |
P478 | volume | 74 |
Q36489406 | A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia |
Q36475355 | A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia |
Q30353864 | A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. |
Q41546064 | Antipsychotic-associated weight gain: management strategies and impact on treatment adherence |
Q38826206 | BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. |
Q39009497 | Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies |
Q89145780 | Clinical Pharmacokinetics of Atypical Antipsychotics: An Update |
Q35728228 | Clinical pharmacology of atypical antipsychotics: an update. |
Q36990173 | Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia |
Q34073723 | Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study |
Q47733836 | Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study |
Q34515834 | LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY |
Q89128745 | Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study |
Q99402127 | Lurasidone and Risk for Metabolic Syndrome: Results from Short and Long-term Clinical Studies in Patients with Schizophrenia |
Q35544274 | Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies |
Q38537910 | Lurasidone in the treatment of schizophrenia: a critical evaluation |
Q36444832 | Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression |
Q47623090 | Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders |
Q92102152 | Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia |
Q39015229 | Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis |
Q38224339 | Safety of antipsychotic drugs: focus on therapeutic and adverse effects |
Q26738850 | Schizophrenia relapse, patient considerations, and potential role of lurasidone |
Q94547427 | Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study |
Q34477219 | The clinical utility of lurasidone in schizophrenia: patient considerations |
Q33619940 | The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. |
Q34486175 | Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia |
Q42682470 | Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records |
Search more.